Authors:
- Muhammad Ahsan Khan, Final Year MBBS Student, Dow University of Health Sciences, Karachi, Pakistan
- Ahya, Third Year MBBS Student, Dow University of Health Sciences, Karachi, Pakistan
- Mishal Shan Siddiqui, Final Year MBBS Student, Dow University of Health Sciences, Karachi, Pakistan
Article Type:
Letter to the Editor
Abstract:
Madam, our current understanding of the COVID-19 virus and its vulnerabilities has not been translated into the approval of its standard line of treatment. COVID-19, although primarily a respiratory ailment, may culminate in acute respiratory distress syndrome, hyper-inflammatory response, sepsis, and multi-organ failure, which often carry a grave prognosis. Drugs addressing such severities of COVID-19 are often limited by their therapeutic indices, bio-availability, and side effects, necessitating the exploration of new avenues to counter them. The ever-evolving field of nanotechnology presents one such example.
Hi, this is a comment.
To get started with moderating, editing, and deleting comments, please visit the Comments screen in the dashboard.
Commenter avatars come from Gravatar.